Stock comparison
Grifols
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GRFS
Grifols
Market cap
$6.48B
Sector
Healthcare
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GRFS | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 55C | 64C | RMD |
| Benjamin Graham | 50C | 67B | RMD |
| Philip Fisher | 46D | 67B | RMD |
| Peter Lynch | 40D | 50C | RMD |
| Joel Greenblatt | 22F | 39D | RMD |
| Charlie Munger | 40D | 61C | RMD |
| Terry Smith | 43D | 65B | RMD |
Side-by-side metrics
| Metric | GRFS | RMD |
|---|---|---|
| Market cap | $6.48B | $29.57B |
| P/E (TTM) | 14.9x | 19.6x |
| EV/EBIT | 12.8x | 17.1x |
| ROIC (TTM) | 5.49% | 19.63% |
| Gross margin | 37.68% | 61.69% |
| Net margin | 5.58% | 27.44% |
| Revenue CAGR 5y | 10.02% | 12.64% |
| EPS CAGR 5y | 20.54% | 30.73% |
| Debt / Equity | 1.8x | 0.1x |
| Dividend yield | 1.65% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GRFS leads on
- Dividend yield1.65%vs 1.14%+31%
- EV/EBIT12.8xvs 17.1x+25%
- P/E (TTM)14.9xvs 19.6x+24%
RMD leads on
- Debt / Equity0.1xvs 1.8x+93%
- Net margin27.44%vs 5.58%+80%
- Market cap$29.57Bvs $6.48B+78%
- ROIC (TTM)19.63%vs 5.49%+72%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.